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DOI 10.1186/s10194-016-0612-2RESEARCH ARTICLE Open AccessMedication overuse headache in Europe
and Latin America: general demographic
and clinical characteristics, referral
pathways and national distribution of
painkillers in a descriptive, multinational,
multicenter study
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Santiago Spadafora9, Marco Pagani10, Rigmor Jensen2* and COMOESTAS ConsortiumAbstract
Background: Medication overuse headache (MOH) is a very disabling and costly disorder due to indirect costs,
medication and healthcare utilization. The aim of the study was to describe general demographic and clinical
characteristics of MOH, along with the national referral pathways and national painkillers distribution in several
European and Latin American (LA) Countries.
Methods: This descriptive cross-sectional observational study included 669 patients with MOH referred to
headache-centers in Europe and LA as a part of the COMOESTAS project. Information about acute medication and
healthcare utilization were collected by extensive questionnaires, supplemented with structured patient interviews.
Results: Triptans were overused by 31 % European patients and by 6 % in LA (p < 0.001), whereas ergotamines
were overused by 4 % in Europe and 72 % in LA (p < 0.001). Simple analgesics were overused by 54 % in Europe
and by 33 % in LA (p < 0.001), while combination-analgesics were more equally overused (24 % in Europe and 29 %
in LA). More European patients (57 %) compared with LA patients (27 %) visited general practitioners (p < 0.001),
and 83 % of European patients compared to 38 % in LA consulted headache specialists (p < 0.001). A total of 20 %
in Europe and 30 % in LA visited emergency rooms (p = 0.007).
Conclusion: There are marked variations between LA and Europe in healthcare pathways and in acute medication
overuse regarding patients with MOH. This should be considered when planning prevention campaigns against
MOH.
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Medication overuse headache (MOH) is a globally preva-
lent and disabling chronic disorder, affecting up to 2 % of
populations [1–6]. In Europe, MOH is a fast growing eco-
nomic burden for society, due to reduced productivity at
work, absenteeism from work, cost of medication, and
healthcare-resource utilization [5].
Epidemiological studies performed on general popula-
tions in western countries report a high degree of health-
care use among patients suffering from chronic headache,
often complicated by MOH, especially in the primary sec-
tor [2, 6, 7]. In addition, a smaller French study found a
high number of contacts to the emergency room (ER)
among patients with chronic headache with and without
medication overuse [8].
However, healthcare systems differ considerably among
nations in regards to organization, referral pathways and
financing of healthcare costs. This may contribute to
international variations in healthcare utilization among
patients with MOH.
Similarly, cultural, economic and political differences
may contribute to an international variation in the use
of acute medications [3, 6, 7, 9, 10]. A Spanish epidemio-
logical study reported simple analgesics as the most con-
sumed type of drug, followed by ergotamines, among
patients with chronic daily headache (CDH) and acute
medication overuse [3]. Scandinavian studies report the
same tendency towards a high preference for simple an-
algesics, accompanied by combination-analgesics [7, 10].
It has been described that patients with MOH in USA
have a higher use of opioids and barbiturates compared
with other nations [6, 9].
The literature regarding healthcare utilization and pat-
tern of medication overuse among patients with MOH
in Latin America (LA) is sparse, which also has been
mentioned by Allena et al. [11]. A better characterization
of this population may assist and direct prevention cam-
paigns and relevant therapy of MOH. Recently, a paper
of the COMOESTAS project concerning clinical and
demographical characteristics of LA patients with MOH
has been published [12].
The current study characterizes and compares the
general demographic and clinical characteristics of
MOH, the referral pathways and the pattern of acute
medication distribution and overuse between European
and LA patients suffering from MOH referred to head-
ache centers, in a multinational, multicenter setup.
Methods
Study design
The present study is a descriptive, cross-sectional, obser-
vational part of the COMOESTAS project. The main
objective of the COMOESTAS project was to compare
MOH-relapse rates six months after a structured,multidisciplinary detoxification program between MOH
patients using a newly developed, electronic headache-
diary system or a paper headache diary, and the main re-
sults are in progress for publication [13]. The highly
positive effect of the treatment program on disability,
depression and anxiety has recently been published
[14].
Study population
Patients referred to six national headache centers or
clinics in Germany (University Hospital, Essen), Denmark
(Danish Headache Center, Copenhagen), Italy (C. Mon-
dino National Neurological Institute, Pavia), Spain (Uni-
versity Clinical Hospital, Valencia), Argentina (Foundation
for Combating Neurological Diseases of Childhood, Bue-
nos Aires) and Chile (Pontificia Universidad Católica de
Chile, Santiago) were included consecutively from August
2008 to February 2009.
Patients were included if they were diagnosed with
MOH according to the revised ICHD-II MOH-criteria
[15], and capable of filling in paper and/or electronic
diaries. The MOH diagnosis was based on 2 months pre-
vious history and at least 1 month with headache diary,
in total 3 months overuse. Exclusion criteria were a
current diagnosis of co-existent, significant and compli-
cating medical or psychiatric illnesses; significant over-
use of ‘pure’ opioids (patients overusing combination
drugs containing opioids were allowed), benzodiazepines
and barbiturates; overuse of alcohol and other drugs of
addiction; current treatment with migraine-prophylactic
drugs, inefficacy of previous, adequate detoxification
programs; pregnancy or breastfeeding; or inability to re-
liably provide medical history.
At inclusion in the program, baseline characteristics
were collected using extensive questionnaires supple-
mented with structured patient interviews. Information
about primary headache diagnoses referred to the time
before medication overuse and was based on the
ICHD-II criteria. Both MOH and primary headache
diagnosis were also revised retrospectively according to
ICHD-III [16].Questionnaire of referral pathway, financing of healthcare
costs, pathways and subsidization of acute medication
In order to obtain relevant background information on
the organization of national healthcare systems, all head-
ache centers were asked how patients were referred to a
headache specialist, and if referral was needed for ER. In
addition, we gathered information on how headache-
related healthcare costs were covered.
Also, background information about medication
subsidization and pathways (over-the-counter (OTC) drugs
versus prescription-requiring analgesics) was obtained.
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Data concerning healthcare utilization and acute medica-
tion overuse were collected by extensive questionnaires
supplemented with structured interviews at the time of
inclusion in the program. Firstly, we focused on the pro-
portion of patients having healthcare consultations
(General practitioner (GP), headache specialist consulta-
tions, and ER visits) and instrumental investigations (EEG,
MR- and CT-scans and X-rays) in the year preceding ther-
apy. Headache specialist consultations mainly included
visits at neurologists and in a few cases neuro-surgeons.
Secondly, this study focused on acute medication overuse
at the time of MOH-diagnosis. This was reported as pro-
portion of patients with specific drug-overuse: Triptans,
ergotamines, simple analgesics, opioids, combination-
analgesics (analgesics combined with codeine, caffeine and/
or antiemetics) or poly-overuse (combination of acute anal-
gesics without overuse of a single drug-type). A patient was
diagnosed with more than one MOH subtype if more than
one type of drug was overused simultaneously. In addition,
proportions of patients with specific drug-overuse were
reported in groups separated according to primary head-
ache diagnosis (migraine, tension type headache (TTH) or
migraine plus TTH).
All results are shown for the total population, grouped
by European and LA headache centers, and sub-grouped
by national headache centers.Statistics
Statistical Package for Social Sciences (SPSS) version 20
was used for statistics. Data were either shown as pro-
portions or as mean and SD in brackets. Chi-square
Fischer’s exact tests were used for 2 × 2 tables and
Pearson’s chi-square tests were used for 2 × 3 tables in
order to compare proportions between Europe and
LA, while Student’s independent t-tests were used to
compare means. A value of p <0.050 was considered as
significant. All p-values were two-tailed.Ethical issues
Local ethics committees from all headache centers ap-
proved the study (the local ethical committee at Essen
University Hospital, local ethical committee at Pavia
University, local ethical committee at Valencia University
Clinical Hospital, Research Ethics Committee at the
Medical School of Pontificia Universidad Católica de
Chile and the Ethics Committee and Biomedical Re-
search at FLENI in Argentina). In Denmark, such studies
are exempted from the approval process, as the study
did not foresee any new pharmacological treatment or
interventions and was hence approved without applica-
tion. All included patients gave informed consent before
taking part.Results
Study population
A total of 1362 patients with potential MOH were
screened in the 6 centers. Of these, 669 were enrolled in
the study (Fig. 1).
The majority were 30–55 years old (67.7 %), females
(79.4 %), and with onset of primary headache in their
teens (64.4 %) (Table 1). The age, gender difference and
age at onset of primary headache were very similar in all
headache centers, and there was no significant difference
between Europe and LA. Baseline characteristics includ-
ing the proportions of primary headache diagnosis, mari-
tal status, educational level and headache frequency are
shown in Table 1.
Noteworthy, there were some significant differences in
the proportion of primary headache diagnosis, although
in general, most of patients had previous migraine or a
combination of migraine and TTH, and only a minority
had TTH as primary headache diagnosis (Table 1).Referral pathway and financing of healthcare costs
To be referred to a headache specialist in Denmark and
Spain, patients need (Table 2) referral by their GP who
function as gatekeeper. In Italy, patients need to be
referred to a specialist by their GP, or can self-refer on
private basis. In Germany, Argentina and Chile, patients
could contact headache specialists directly by self-referral.
There was free access for ER in all countries (Table 2).
In the European countries, the governments finance
headache specialist consultations in full, except in Italy,
where a partial contribution is requested from the
patients. In LA, the costs of headache specialist consul-
tations are covered by private healthcare assurances or
out of own pocket. Financing of costs of instrumental in-
vestigations is presented in Table 2.Headache-related healthcare utilization
Only 26.5 % of the LA patients had GP consultations for
their headache in the year preceding inclusion in the
study, compared with 56.7 % of the European patients
(p < 0.001) (Fig. 2). It should be mentioned that only
6.8 % of the Italian patient group were screened through
preliminary GP visits, which is far lower than the pro-
portion of patients from LA (Fig. 3). In contrast, 77.1 %
of the German patients had GP consultations, and of
those, 35.4 % visited the GP more than 6 times per year,
corresponding to a visit more than every second month
(see Additional file 1: Table S1).
The vast majority of European patients (82.7 %), espe-
cially the Italian group (95.7 %), had seen a headache
specialist prior to admission to the headache center,
while this was only the case for 37.6 % of the LA pa-
tients (p < 0.001) (Figs. 2 and 3).
Patients screened for 
participation
N = 1362
a) Excluded
N = 693
Patients included
N = 669
Denmark
N = 125
Germany
N = 101
Italy
N = 117
Spain
N = 92
Argentina
N = 126
Chile
N = 108
Fig. 1 Study population. The flowchart illustrates the population. a)Patients (N = 444) were excluded for 3 main reasons: previous detoxifications
(mostly in the European Centers), wrong referral diagnosis (mostly in the LA Centers) and refusal to participate (equal distribution between EU
and LA areas). Furthermore, 191 patients did not fullfill the criteria after filling out headache diary or did not have an internet spot available at
home or nearby. Finally, 58 patients were excluded because they did not show up to the following visit or dataset was incomplete. Of the
included patients, 435 came from Europe and 234 came from Latin America
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visits, compared to 20.4 % of the European patients (p =
0.007) (Fig. 2). The proportions of patients with ER visits
varied considerably among all centers, e.g., in Spain,
50.6 % of the patients visited the ER, in contrast to only
6.0 % of the Italian patient group and 20.6 % of the Ar-
gentinian patient group (Fig. 3).
The frequencies of headache-related instrumental in-
vestigations are presented in Table 1. There was no sig-
nificant difference between Europe and LA.Characterization of medication overuse patterns
While ergotamines were the most frequently overused an-
algesics among patients from LA (72.2 %), they were only
overused by 3.7 % of the European patients with MOH (p
< 0.001) (Fig. 4). In contrast, triptans were overused by
30.8 % of European patients with MOH and only by 5.6 %
of LA patients (p < 0.001). The same pattern for ergota-
mines and triptans was seen when separating patients ac-
cording to primary headache diagnosis (Table 3). Among
the European patient groups, the Spanish had the lowest
percentage of triptan overusers (13.0 %) and the highest
percentage of ergotamine overusers (7.6 %) (Fig. 5). In
contrast, Italy had the highest rate of triptan overusers
among the European patients (41.9 %) (Fig. 5).
Simple analgesics were overused in all patient groups,
corresponding to 46.9 % in the study population, and
15.4 % were daily users (Additional file 2: Table S2). In
LA, 33.3 % of the patients overused simple analgesics
(Fig. 4). However, significantly more patients from Europe(54.3 %) overused simple analgesics (p < 0.001), and note-
worthy it was the case for 80.4 % of the Spanish group.
Combination-analgesics were often overused in Chile
(59.3 %), Denmark (37.6 %), Germany (22.8 %) and Italy
(21.4 %), while they were only overused by a minority of
MOH patients in Spain (8.7 %) and Argentina (3.2 %)
(Fig. 5). No significant difference in terms of overuse of
combination-analgesics was observed between Europe
and LA (P = 0.14), except among the group of patients
with previous migraine (Table 3). In general, only a small
proportion was diagnosed with an opioid-overuse
(1.5 %) or poly-overuse (2.2 %). There was no significant
difference in duration of medication overuse between
Europe and LA (P = 0.13) (Additional file 2: Table S2).
For the total population 59.8 % had a medication over-
use for 1–5 years, and 23 % for more than 5 years.
The policy about whether a particular analgesic requires
prescription is different among all the countries, as in
the case with medication subsidization (summarized in
Table 4).
Most patients in the study population only had a sin-
gle MOH diagnosis (75.6 %), while 23 % had two MOH
diagnoses and 1.5 % had three kind of medication over-
use (Additional file 3: Table S3).
Discussion
The findings in this study demonstrate a marked variability
between Europe and LA regarding general and clinical
characteristics of patients as well as the organization of
healthcare systems, and headache-related healthcare
utilization, medication-overuse and medications availability.
Table 1 Baseline Characteristics
Denmark Germany Italy Spain Argentina Chile Europe Latin
America
p-value Total
N 125 101 117 92 126 108 435 234 669
Age, years <30 13.6 26.7 18.8 15.2 31.2 20.4 18.4 26.1 21.1
30–55 71.2 63.4 72.6 70.7 58.4 70.4 69.7 63.7 0.058 67.7
>55 15.2 9.9 8.5 14.1 10.4 9.3 12.0 9.8 11.2
Gender, female 77.6 74.3 82.1 80.4 80.2 81.5 78.6 80.8 0.55 79.4
High educational levela 87.2 40.4 71.8 49.5 80.2 67.6 64.4 74.4 0.009* 67.9
Marital status, married 70.4 52.0 58.1 68.1 50.8 55.6 62.4 53.0 0.021* 59.1
Primary headache
diagnosis
Migraineb 30.4 80.2 82.9 46.7 72.2 79.6 59.5 75.6 65.2
TTHb 26.4 2.0 0.9 16.3 5.6 1.9 11.7 3.8 <0.001* 9.0
Migraine and
TTHb
43.2 17.8 16.2 37.0 22.2 18.5 28.7 20.5 25.9
Age of onset of primary headache, years 23.4
(13.0)
18.1 (9.2) 14.1
(6.0)
18.9
(9.9)
16.2 (6.2) 19.7
(10.1)
18.8
(10.5)
17.8 (8.4) 0.22 18.4
(9.8)
Headache frequency, days/monthc 25.8 (5.5) 25.1 (5.6) 23.3
(6.0)
23.6
(5.0)
22.1 (6.4) 23.0 (5.7) 24.5 (5.7) 22.5 (6.1) <0.001* 23.8
(5.9)
Duration of overuse in
years
<1 13.6 21.8 11.1 16.3 19.0 22.2 15.4 20.5 17.2
1–5 67.2 54.5 58.1 57.6 61.9 57.4 59.8 59.8 0.13 59.8
>5 19.2 22.4 30.8 26.1 19.0 20.4 24.8 19.7 23.0
EEGd 7.3 31.8 0.9 4.7 8.0 2.8 10.0 5.6 0.055 8.4
Scans (CT and MR)d 29.3 42.3 20.5 36.4 40.0 21.3 31.0 31.3 0.93 31.1
X-raysd 5.7 21.2 2.6 14.1 12.8 0.9 9.8 7.3 0.32 8.9
Age, gender, educational level, marital status, primary headache type: Proportion of patients in percent. Age of onset of primary headache and headache
frequency: Mean (SD). Duration of overuse: Percent of patients categorized into three intervals. EEG, Scans and X-rays: Percent of patients, who had these instru-
mental investigations performed in the year preceding therapy
TTH tension type headache, EEG electro encephalogram, CT computer tomography scan, MR magnetic resonance scan
aHigh educational level = High/technical school or university degree
bMigraine = Migraine with aura, migraine without aura and chronic migraine. TTH = episodic and chronic forms
cHeadache frequencies refer to the time of inclusion in the study and thereby to the MOH diagnosis
dN = 643
*p < 0.05. p-values correspond to comparison between Europe and Latin America
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the distribution of primary headache diagnoses between
Europe and LA countries. Considering the significantly
higher level of education for LA patients and the fact
that they have to pay out of their own pocket in order to
receive the attention of a headache specialist, it is pos-
sible that the observed difference may be related to a dif-
ferent social class of subjects with higher income, more
frequently single and tend to be younger. Of course cul-
tural or real epidemiological differences cannot be ruled
out.
The inhomogeneous distribution of primary headache
diagnoses may theoretically have affected the propor-
tions of the types of overused analgesics, since e.g., trip-
tans and ergotamines are recommended for treatment
for migraine only. However, when separating the groups
according to primary headache diagnosis, we almost
found the same results as in the whole group with a few
exceptions as mentioned.Only a minority of the patients reported pure TTH as
primary headache. This could be due to less disability
compared to patients with concomitant migraine, con-
tributing to fewer referrals to headache centers. Accord-
ing to previously published Scandinavian studies
concerning MOH, approximately 20–30 % percent suf-
fered from pure TTH as primary diagnosis [17, 18],
which is comparable to the findings in the Danish and
Spanish group in this study.
Prior studies have characterized the use of healthcare
in the general population [7, 10, 19], and our patients
with MOH presented a multifold higher rate of access to
headache specialists. This reflects that our study popula-
tion was much more affected by headache, and empha-
sizes the unmet need for focused prevention and
management strategies.
The fact that far more European patients had consul-
tations with GPs and headache specialists compared
with LA patients - while the latter more frequently
Table 2 Referral pathway and financing of healthcare costs for patients
Denmark Germany Italy Spain Argentina Chile
Referral pathways
Referral needed for headache
specialist consultation
Yes No Yes or self-refer on
private basis
Yes No No
Who are able to refer the patients
to a headache specialist?
GPa – GP GP – –
Other specialists Other specialists
ERa ER
Other doctors
Referral needed for emergency
room visits
No No No No No No
Financing of healthcare costs for patients
Free Access GP GP GP GP – GP
Headache
Specialist
Headache
Specialist
Headache
Specialistb
Headache
Specialist
–
ER ER ERc ER ER
EEG, MR-, CT-
scan and X-rays
EEG, MR-, CT-
scan and X-rays
EEGb, MR-d, CT-
scand and X-rayse
EEG, MR-, CT-
scan and X-rays
MR-, CT-scan
and X-rays
Private healthcare assurance – – – – GP GP
Headache
Specialist
Headache
Specialist
ER ER
EEG, MR-, CT-
scan and X-rays
EEG, MR-, CT-
scan and X-rays
Out of own pocket – – – – – GP
Headache
Specialistb
Headache
Specialist
Headache
Specialist
ERc – ER
EEGb, MR-d, CT-
scand and X-raysd
– EEG, MR-, CT-
scan and X-rays
GP general practitioner, ER emergency room, EEG electro encephalogram, CT computer tomography scan, MR magnetic resonance scan
aReferral after a relevant therapy course performed by a general neurologist
bPatients < 6 years or > 65 years are exempted for covering the healthcare costs. Without exemption contribution is required according to income
cFree access if appropriate request (real emergency)
dPatients < 6 years or > 65 years are exempted for covering the healthcare costs. Without exemption contribution is required depending on income
Free access = government covers the costs
Fig. 2 Headache-related healthcare consultations among patients with medication overuse headache in Europe and Latin America. The bar chart
compares the proportion of patients (in percent) from Europe and Latin America with general practitioner (GP) consultations, headache specialist
consultations and emergency room (ER) visits in the year preceding inclusion of the study. *p < 0.05
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Fig. 3 Healthcare consultations among patients with medication overuse headache. The bar chart presents the proportion of patients (in
percent) from each headache clinic with general practitioner (GP) consultations, headache specialist consultations and emergency room (ER) visits
in the year preceding inclusion of the study
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healthcare systems. Headache centers were non-existing
in Chile (the first one was activated within the initiatives
of the COMOESTAS Project 2008–2010) and only one
headache center was available in Buenos Aires, a city
with several millions of inhabitants. It must be noted
that another possible reason for less GP and headache
specialist contacts in LA could be less focus in society
on headache as a disorder requiring therapy. We have
observed a high frequency of EEG examinations in
Germany in contrast to the existing guidelines [20] and
practice in other countries. In general, EEG is notFig. 4 Type of overused analgesics in Europe and Latin America. The bar c
Latin America with specific drug-overuse. A single patient can be diagnoserecommended for the diagnosis of headache but national
practice may still vary.
In general, it seems that the healthcare system is not
used in the appropriate manner, because a considerable
proportion of MOH patients, both from Europe and LA,
seek help at the ER, which does not seem as the optimal
setting for managing a chronic condition. Furthermore,
when considering the very high use of GP visits in some
European countries, it could be important to clarify
whether some European patients used the healthcare
system at too high extent, thus contributing to an un-
necessarily increased economic burden for society. Inhart compares the proportion of patients (in percent) in Europe and
d with more than one type of overuse. *p < 0.05
Table 3 MOH sub-diagnosis in relation to primary headache diagnosis
Primary headache diagnosis Acute analgesics Denmark Germany Italy Spain Argentina Chile Europe Latin America P-value Total
N 38 81 97 43 91 86 259 177 436
Migraine Ergotamines 5.3 1.2 4.1 2.3 81.3 62.8 3.1 72.3 <0.001* 31.2
Triptans 55.3 37.0 47.4 16.3 4.4 8.1 40.2 6.2 <0.001* 26.4
Simple analgesics 26.3 60.5 29.9 79.1 26.4 34.9 47.1 30.5 0.001* 40.4
Opioids 5.3 6.2 0.0 0.0 0.0 0.0 2.7 0.0 0.045 1.6
Combination-analgesics 18.4 21.0 21.6 4.7 3.3 62.8 18.1 32.2 0.001* 23.9
Poly-overuse 5.3 2.5 3.1 4.7 0.0 1.2 3.5 0.6 0.54 2.3
N 33 2 1 15 7 2 51 9 60
TTH Ergotamines 0.0 0.0 0.0 6.7 100.0 100.0 2.0 100.0 <0.001* 16.7
Triptans 0.0 0.0 0.0 6.7 0.0 0.0 2.0 0.0 1.00 1.7
Simple analgesics 81.8 50.0 100.0 86.7 42.9 0.0 82.4 33.3 0.005 75.0
Opioids 3.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 1.00 1.7
Combination-analgesics 36.4 100.0 0.0 13.3 0.0 50.0 31.4 11.1 0.42 28.3
Poly-overuse 3.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 1.00 1.7
N 54 18 19 34 28 20 125 48 173
Migraine and TTH Ergotamines 3.7 0.0 0.0 14.7 14.3 40.0 5.6 66.7 <0.001* 22.5
Triptans 33.3 22.2 15.8 11.8 3.6 5.0 23.2 4.2 0.003* 17.9
Simple analgesics 38.9 66.7 63.2 79.4 35.7 55.0 57.6 43.8 0.13 53.8
Opioids 3.7 0.0 0.0 0.0 0.0 0.0 1.6 0.0 1.00 1.2
Combination-analgesics 51.9 22.2 21.1 11.8 3.6 45.0 32.0 20.8 0.19 28.9
Poly-overuse 1.9 0.0 10.5 2.9 0.0 0.0 3.2 0.0 0.58 2.3
Percentage of patients with specific MOH sub-diagnosis related to primary headache diagnosis. Number of each group are included in the table. Migraine includes
forms with aura, without aura and chronic forms. TTH (Tension Type Headache) includes episodic and chronic forms. p-values correspond to comparison between
Europe and Latin America. *p < 0.05
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patients with MOH may contribute to fewer, but more
relevant healthcare contacts.
It can be difficult to compare the use or ER accesses
across different health care systems, since primary care sys-
tems and emergency systems may be fundamentally differ-
ent. In this study there was free access in all countries. The
findings concerning medication overuse in Europe are in
line with results reported in previous studies from Euro-
pean countries [3, 7, 10]. In the present study, simple anal-
gesics were overused in 80 % of the MOH patients from
Spain, which is in agreement with the findings of a previous
Spanish study, where simple analgesics also were the most
overused drugs [3]. The results from the Danish patient
group, showing highest preference for simple analgesics,
followed by combination-analgesics, were supported by two
previous Scandinavian studies [7, 10]. Also in the case of
the ergotamine overuse in LA, our findings are reinforced
by a recently published review that reports a high preva-
lence of ergotamine-overuse in LA, and a relatively high
prevalence of triptan-overuse in Europe [21].
Ergotamines are highly potent drugs for treating mi-
graine. In LA, ergotamines are sold as OTC analgesics atlow prices in contrast to Europe where ergotamines
require prescription. This may explain the widespread
use in LA. In the eighties and nineties, overuse of ergot-
amines was a major problem in Europe, and a German
study from 2002 reported that 13 % of the patients with
MOH overused ergotamines [22]. The availability and, for
some countries, the subsidization of triptans in Europe
explain the marked decrease in ergotamine overuse and
the associated increase in triptan overuse. The distribution
policy of triptans, based on prescriptions, obviously did
not succeed in deterring overuse. The ergotamine-triptan
switch observed in Europe has also been reported in the
United States [23], thus suggesting that replacement of
ergotamines by triptans is likely to occur in the future in
LA. It should be mentioned, that even though prescription
was required for ergotamines in Spain, many patients
managed to obtain ergotamines without. This could
explain why patients from the Spanish group had the
highest European proportion of ergotamine-overuse.
This study also reported other differences in the medi-
cation overuse pattern among the European countries.
Italian patients tended to use more triptans than other
European patients, which may be explained by the fact
Fig. 5 Type of overused analgesics. The bar chart compares the proportion of patients (in percent) from each headache clinic with specific drug-
overuse. A single patient can be diagnosed with more than one type of overuse
Find et al. The Journal of Headache and Pain  (2016) 17:20 Page 9 of 12that triptans are the only analgesics with subsidization in
Italy. Next to simple analgesics, triptans were the most
often overused acute medication in Germany, even
though there was no subsidization to triptans. Never-
theless, some triptans, e.g., naratriptan, are available
as OTC analgesics. In Denmark, most simple analgesics
and combination-analgesics are OTC analgesics, which
probably made them the most often overused analgesics.
The same phenomenon was observed in the German
patient group. In Spain, the far most common overused
analgesics were simple analgesics, which are available as
OTC and subsidized.
In Argentina, simple analgesics are OTC analgesics, as
in Denmark, Spain and Germany, and may also in this
case contribute to overuse in almost one-third of the
Argentinian patients. In Chile, combination-analgesics
were overused almost as often as ergotamines. Both
kinds of analgesics are sold as inexpensive OTC drugs.
Even though this study describes huge international
variations in particular patterns of medication overuse,
the underlying factors encouraging medication overuse
seem to be the same in all countries: high availability
and low prices. This is supported by previously pub-
lished Asian studies, which reported a high prevalence
of OTC analgesic overuse too [24–26]. Thereby, high
availability and low costs of acute medication are global
challenges for preventing MOH. When having the
knowledge about which analgesics that are most com-
monly overused, specifically targeted clinical andpolitical initiatives can be more easily initiated, e.g.,
smaller packages of analgesics and focused prevention
campaigns spreading out information about the nature
of MOH, thereby changing patients’ behavior.Methodological considerations
To our knowledge, no previous study has described and
compared general demographic and clinical characteris-
tics of MOH, along with the referral pathways and na-
tional painkillers distribution in several European and
LA Countries. We did this multicenter, multinational
setup in a large MOH population, which is a major
strength of this study. The present study is unique as it
describes patients accessing headache centers and spe-
cialized care, carefully classified by means of prospective
diaries. The fact that the study was conducted on pa-
tients attending specialized center of course represents a
selection bias making this study less applicable to pa-
tients in the primary sector and therefore prevents
generalization of the results.
It is noteworthy that in the original study design
MOH patients overusing barbiturates or pure opioid
overuse were excluded, as well as patients with benzodi-
azepine overuse [13, 14]. This makes the study less ap-
plicable for specific groups of patients with high use of
barbiturates, opioids and benzodiazepines. It should also
be mentioned that patients with significant comorbid
psychiatric illnesses were excluded. However, this study
Table 4 Medication pathways and subsidization
Denmark Germany Italy Spain Argentina Chile
OTC analgesicsa – – – – Ergotamines Ergotaminesk
– Triptansd – – Triptansl
Simple analgesicsb Simple analgesicse Simple analgesicsg Simple analgesics Simple analgesics
– – – – –
Combination-
analgesicsc
Combination-
analgesicsf
Combination-
analgesics
– Combination-
analgesicsm
Prescription needed Ergotamines Ergotamines Ergotamines Ergotaminesh – –
Triptans Triptansd Triptans Triptans Triptans –
Simple analgesicsb Simple analgesicse Simple analgesics – – –
Opioids – Opioids Opioids Opioids Opioids
Combination-
analgesicsc
Combination-
analgesicsf
Combination-
analgesics
– Combination-
analgesics
–
Analgesics with
subsidization
Ergotamines – – Ergotamines – –
Triptans Triptans Triptans Triptansj
– – Simple analgesics Simple analgesics
Opioids – Opioids Opioids
– – Combination-
analgesicsi
Combination-
analgesics
Analgesics without
subsidization
– Ergotamines Ergotamines – Ergotamines Ergotaminesk
– Triptans – – – Triptansl
Simple analgesicsb Simple analgesics Simple analgesics – – Simple analgesics
– Opioids Opioids – – Opioids
Combination-
analgesicsc
Combination-
analgesics
Combination-
analgesics
Combination-
analgesicsi
– Combination-
analgesicsm
aOver-the-counter analgesics
bMost simple analgesics are OTC. Prescription is only required for large packages or higher doses. Only prescribed simple analgesics are subsidized
cCombination-analgesics containing opioids, phenazone and ergotamine require prescription with a few exceptions. Only ergo-caffeine are subsidized
dMost triptans require prescription. Few triptans, e.g., Naratriptan, are OTC
eMost simple analgesics are OTC, except Ibuprofen 600 mg
fCombination-analgesics containing caffeine do not require prescription, while those containing opioids do
gSimple analgesics are OTC. However, prescription is used at least in 60 %
hErgotamines require prescription. Nevertheless, many patients manage to acquire it without
iSome compounds are subsidized
jTriptans are only subsidized partially
kErgotamines are inexpensive and easily available. All kind of ergotamins are combined with either caffeine, acetoaminophen or NSAIDS
lTriptans are expensive and available only at pharmacies
mCombination-analgesics are inexpensive. There are no combinations with codeine. Most common combination-analgesics contain caffeine, dipirone, chlorphena-
mine and ergotamine
Find et al. The Journal of Headache and Pain  (2016) 17:20 Page 10 of 12is applicable to patients with less complex psychiatric
disorders and less severe MOH cases, representative for
a significant part of the clinical MOH population in pri-
mary and specialized care. However, it may be difficult
to compare use of emergency across health care systems
due to different organizations of the link between the
primary care sectors and the emergency systems. In
some countries, there may be differences in how emer-
gency rooms and emergency departments are organized.
This study does not distinct between that.
The patients were included in 2008 and 2009. Some
changes concerning acute medication overuse and
healthcare utilization may have occurred since then.The present data remain however important as, to
the best of our knowledge, no other study has pro-
vided relevant information on this topic in the subse-
quent years. It could be interesting to repeat the
study for comparing with our results.Conclusion
MOH definitely represent a serious cross-continental
issue, although demographic and clinical variability may
exist, along with differences in referral patterns, use of
healthcare resources and overuse of acute medications
overuse in the 2 continents.
Find et al. The Journal of Headache and Pain  (2016) 17:20 Page 11 of 12A clear message from our data is this: drugs are over-
used when they are easily accessible and at low price. A
focused effort to recognize and treat patients with MOH
may contribute to fewer, but more targeted healthcare
contacts. Furthermore, clinical and political initiatives
for awareness and prevention campaigns based on infor-
mation of MOH can be better facilitated and targeted
when having the knowledge about which types of anal-
gesics that are more likely to become overused by head-
ache sufferers in a particular part of the world.
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